NCT04586985 - Safety, Tolerability and Pharmacokinetics of FTX-6058 | Biotech Hunter

Enrollment

109

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

November 15, 2022

Study Completion Date

November 15, 2022

Conditions

Healthy Adult SubjectsSickle Cell Disease

Interventions

DRUG

FTX-6058/placebo oral capsule(s)

Subjects will receive FTX-6058 or matching placebo.

DRUG

FTX-6058/placebo oral capsule(s)

Subjects will receive FTX-6058 or matching placebo.

DRUG

FTX-6058 - Two Dosing Periods

Subjects will receive FTX-6058

DRUG

FTX-6058 / Midazolam Syrup

Subjects will receive FTX-6058 and midazolam syrup

DRUG

FTX-6058/placebo oral capsule(s)

Subjects will receive FTX-6058 or matching placebo.

Trial Locations (2)

Atlanta Center for Medical Research - Sickle Cell Subjects Only, Atlanta

Altasciences Clinical Kansas, Inc. - Healthy Adults Subjects Only, Overland Park